Stocks surged after President Donald Trump said he will be meeting with his Chinese counterpart, Xi Jinping, at the upcoming G-20 summit.US Marketsread more
In a tweet, Trump said that he and Xi "had a very good telephone conversation," and that "our respective teams will begin talks prior to our meeting."Politicsread more
A Bloomberg News report Tuesday morning said the White House had looked at such a move back in February.Marketsread more
President Donald Trump on Tuesday announced that he will not nominate acting Defense Secretary Patrick Shanahan to hold the position in a permanent capacity. Army Secretary...Politicsread more
The move is part of a larger trend that saw the survey's 179 participants move away from risk and toward positions that reflect fear of a coming economic slowdown spurred by a...Marketsread more
Trump starts the campaign season in an unusual spot for a president: overseeing a strong economy but facing low approval ratings.Politicsread more
The major Wall Street analysts say Facebook's Project Libra has a bright future.Marketsread more
Democratic frontrunner Joe Biden on Monday appealed to a billionaire Republican donor for fundraising help in his presidential campaign. But the financier, Trump-supporting...Politicsread more
These are the stocks posting the largest moves midday.Market Insiderread more
Shares of Beyond Meat soared 18% Tuesday morning, surpassing $200 per share and setting a new all-time high.Food & Beverageread more
Google Calendar was down around the world on Tuesday, though the Google Calendar app still worked.Technologyread more
The U.S. Federal Trade Commission seeks a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired, an FTC official told a legal conference on Friday.
The antitrust agency alleges that the way drugmakers settle patent-related lawsuits hurts consumers by making drugs more expensive. In the settlements, makers of brand-name drugs pay millions of dollars to generics companies while they delay putting their products on the U.S. market.
In June, the U.S. Supreme Court ruled that the FTC may challenge the deals in federal courts.
A panel moderator at the American Bar Association's spring antitrust meeting asked Deborah Feinstein, the director of the FTC's Bureau of Competition, what developments to expect in the coming year.
"My hope is that we get a billion-dollar settlement in one of the patent-settlement, pay-for-delay cases,'' Feinstein responded, giving no indication that any settlement was imminent. The FTC's long-running lawsuits are not close to going to trial.
"In all truth, that is one of the biggest priorities we have,'' she said. "The consumer harm there is extremely significant, and so we have a tremendous amount of resources there and hope to come out with a victory one way or another in those cases.''
Generic drugmakers like the "pay for delay'' arrangements because if they bring out their products before patent-infringement litigation is over, they run the risk of paying triple damages on sales if they are found to have infringed.
The FTC shares antitrust authority in the United States with the U.S. Justice Department.